EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates

Hamed Wafa, Nils C H van Creij, Michael Guenther, Maxim Noeparast, Jose Daniel Subiela, Angelika Terbuch, Dora Niedersuess-Beke, Zoran Culig, Steffen Ormanns, Renate Pichler

Cancer Treatment Reviews · 2026-07 · 148 · 103173

DOI: 10.1016/j.ctrv.2026.103173 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026-07. Verfasst von Hamed Wafa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesUrinary Bladder NeoplasmsCarcinoma, Transitional CellAntineoplastic Agents, ImmunologicalHumansAntibodies, Monoclonal, HumanizedMolecular Targeted TherapyBiomarkers, Tumor

Stichwörter der Autor:innen

Antibody-drug conjugatesBladder cancerDisitamab vedotinHER2IHCTrastuzumab deruxtecanUrothelial cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesERBB2 protein, humanAntineoplastic Agents, ImmunologicalAntibodies, Monoclonal, HumanizedBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
  • Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
  • Institute of General Pathology, Medical University Innsbruck, Innsbruck, Austria.
  • Translational Oncology, II. Med Clinics Hematology and Oncology, Augsburg, Germany.
  • Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain.
  • Division of Clinical Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria.

Zitieren

APA

Wafa, H., van Creij, N. C. H., Guenther, M., Noeparast, M., Subiela, J. D., Terbuch, A., Niedersuess-Beke, D., Culig, Z., Ormanns, S., & Pichler, R. (2026). Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates. Cancer Treatment Reviews, 148, 103173. https://doi.org/10.1016/j.ctrv.2026.103173

Vancouver

Wafa H, van Creij NCH, Guenther M, Noeparast M, Subiela JD, Terbuch A, et al. Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates. Cancer Treatment Reviews. 2026;148:103173. doi:10.1016/j.ctrv.2026.103173

BibTeX
@article{Wafa2026,
  author = {Wafa, Hamed and van Creij, Nils C H and Guenther, Michael and Noeparast, Maxim and Subiela, Jose Daniel and Terbuch, Angelika and Niedersuess-Beke, Dora and Culig, Zoran and Ormanns, Steffen and Pichler, Renate},
  title = {Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates},
  journal = {Cancer Treatment Reviews},
  year = {2026},
  volume = {148},
  pages = {103173},
  doi = {10.1016/j.ctrv.2026.103173}
}
Kostenlos starten →